Case Report

Beta-Human Chorionic Gonadotropin Producing Osteosarcoma of the Sacrum in a 26-Year-Old Woman: A Case Report and Review of the Literature

Ryan Glass, Jaya Ruth Asirvatham, Leonard Kahn, and Mohamed Aziz

Department of Pathology, North Shore Long Island Jewish, New Hyde Park, NY 11040, USA

Correspondence should be addressed to Ryan Glass; rglass01@gmail.com

Received 8 November 2014; Accepted 22 January 2015

Academic Editor: Katsuyuki Aozasa

Copyright © 2015 Ryan Glass et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ectopic secretion of beta-human chorionic gonadotropin is considered a poor prognostic marker in epithelial tumors. However, very few cases have been reported in sarcomas. We present the case of a 26-year-old female who presented with a metastatic osteosarcoma. She underwent usual testing prior to starting treatment and was found to have elevated levels of beta-human chorionic gonadotropin. As the patient was not pregnant, another source of beta-human chorionic gonadotropin secretion had to be considered. The tumor cells demonstrated positive staining for beta-human chorionic gonadotropin by immunohistochemistry, and serum levels of beta-human chorionic gonadotropin were used to monitor tumor progression and response to chemotherapy. We review the literature and discuss a potential role of beta-human chorionic gonadotropin in the treatment of such patients.

1. Introduction

Beta-human chorionic gonadotropin (β-hCG) is normally produced by syncytiotrophoblasts of the placenta and may also be secreted by germ cell neoplasms. Ectopic secretion of β-hCG by epithelial tumors, including bladder, lung, and colorectal cancers, is a recognized phenomenon associated with a poorer prognosis [1]. However, ectopic β-hCG expression has been less frequently reported in sarcomas, with very few known in osteosarcomas. We present a case of a female patient with an osteosarcoma who was incidentally discovered to have elevated serum β-hCG levels. Immunohistochemical staining identified the tumor as the source of the hormone and serum levels were used to monitor the tumor’s response to treatment and progression.

2. Case Report

A 26-year-old female presented to an outside institution with pelvic pain over the previous several months. A CT scan revealed a large lytic lesion in the pelvis, multiple paraspinal soft tissue masses, parasacral soft tissue masses, and a lytic lesion in the L4 vertebral body (Figures 1(a) and 1(b)), with a chest X-ray showing multiple lung lesions. Biopsies of the paraspinal masses revealed a high-grade sarcoma. She was seen at our institution approximately one month later. Biopsies taken from the pelvic mass showed identical features to those of the paraspinal masses. During the initial workup, the patient was found to have serum β-hCG levels of 693 mIU/mL and pregnancy was suspected. However, pregnancy was ruled out as her menstrual bleeding was 3 weeks earlier and she had never been sexually active. The possibility of a β-hCG secreting tumor was considered, and the tumor cells stained strongly positive for β-hCG. The final diagnosis was that of a β-hCG secreting osteogenic sarcoma. As metastases were present at the time of diagnosis, the patient was not a surgical candidate. Chemotherapy with methotrexate and ifosfamide was initiated. Serum β-hCG levels, which were monitored throughout the patient’s course, transiently fell after each treatment. This drop correlated with radiologic response to treatment. However, as this was an aggressive tumor, it tended to regrow in spite of treatment. These periods of growth were accompanied by rising β-hCG levels.
Figure 1: CT Scan showing tumor invasion of sacrum: left and right surrounding parasacral soft tissue (a), and L4 vertebral body (b).

Figure 2: Osteosarcoma of pelvis demonstrating hyperchromatic spindle-shaped tumor cells associated with matrix production (a) and osteoid formation (b). Tumor stains positive for $\beta$-hCG (c) (Hematoxylin-eosin [a, b], original magnifications $\times4$ [c], $\times20$ [a-b]).

3. Microscopic Description

Microscopic examination of the biopsy specimens revealed a mass composed primarily of malignant spindle cells, infiltrating bone and soft tissue with no recognizable architectural pattern. The tumor cells appeared cytologically atypical with focal areas of pleomorphism and mitoses up to 4 per 10 high-power fields. Multiple areas of osteoid formation and scattered benign appearing giant cells were noted within the tumor (Figures 2(a) and 2(b)). Initial studies were positive for vimentin, focally positive for CD68, and negative for cytokeratin, CK7, CD34, and S100.

Additional studies were requested after the patient was found to have high levels of $\beta$-hCG (Figure 2(c)). These revealed the tumor to be positive for $\beta$-hCG and negative for placental alkaline phosphatase, epithelial membrane antigen, smooth muscle antigen, desmin, myogenin, and CD31.

4. Discussion

To the best of our knowledge, very few cases of $\beta$-hCG secreting osteosarcomas exist in the literature (Table 1). The mean age of these patients was 22 years (range: 5–57 years) with
Table 1: Previously reported cases of β-hCG producing osteosarcoma.

| Author            | Age | Sex | Chemotherapy                  | Status                                    |
|-------------------|-----|-----|--------------------------------|-------------------------------------------|
| Kalra et al. [2]  | 21  | F   | Vinblastine, bleomycin, and cisplatin | Died during treatment                     |
| Tuy et al. [3]    | 37  | F   | None                           | Died from disease progression             |
| Boss et al. [4]   | 57  | F   | Doxorubicin and cisplatin; ifosfamide and etoposide; Cyclophosphamide and imatinib; E7080 | Initial success with E7080, followed by disease progression |
| Masrouha et al. [5]| 17  | F   | Regimen unknown                | Lung metastases                           |
|                   | 14  | M   | Regimen unknown                | Died during treatment                      |
|                   | 17  | F   | Regimen unknown                | No recurrence                             |
|                   | 17  | M   | Regimen unknown                | Lung metastases                           |
|                   | 5   | M   | Regimen unknown                | Died during treatment                      |
| Leidinger et al. [6]| 18 | F   | COSS-96; COSS-96 with carboplatin, etoposide, and RT | Lost to follow-up                      |
| Oshrine et al. [7]| 14  | F   | Doxorubicin and ifosfamide, cisplatin regimen | Disease free after 6 months               |
| Ordonez et al. [8]| 26  | F   | Unknown                        | Unknown                                   |
| Our case          | 26  | F   | Methotrexate and ifosfamide    | Died from progressive disease             |

nine females and three males. In cases where serum β-hCG testing was performed, levels as high as 5000 mIU/mL have been reported although the significance of this is unclear [2]. Of the ten patients with available follow-up, eight have died or experienced lung metastases. One of Masrouha et al.’s patients, however, experienced a complete response although it should be noted that cells of the initial biopsy stained weakly positive and those from the excised tumor stained negative [5]. Leidinger et al.’s patient also remained disease free, although follow-up was only available for six months [6]. As the majority of these tumors demonstrated an unfavorable rapidly progressing course, this paraneoplastic feature may portend poor prognosis in osteosarcomas.

It is difficult to ascertain the true incidence of β-hCG producing osteosarcomas. As most cases in the literature (as well as ours) were discovered incidentally by urine pregnancy screening, it is likely that many others are missed, especially in male patients. To determine the rate of β-hCG positivity, Ordonez et al. retrospectively stained 11 osteosarcoma specimens for β-hCG, finding that only two (18.2%) stained positive [8]. In a more recent study, by Masrouha et al., 5 of 32 (15.6%) retrospectively stained specimens showed β-hCG positivity, 3 of which were from male patients [5].

The significance of β-hCG-staining in tumor cells as well is unclear. While it has been shown that staining intensity in carcinomas correlates with tumor grade [1], it is unknown if this relationship holds in osteosarcomas as very few studies have examined this. Leidinger et al. reported positive staining in dedifferentiated metastases of negatively staining primary tumors [6], and Masrouha et al. reported that four of the five cases stained positively in histologically high-grade tumors [5]. However, Oshrine et al. reported no morphological differences between β-hCG-positive and β-hCG-negative cells within the same tumor [7]. In our case, the tumor appeared of low-grade and, similar to Oshrine’s findings, no noticeable differences were seen between β-hCG-positive and β-hCG-negative areas.

X-ray crystallography of β-hCG revealed a quaternary structure containing a “cysteine knot,” making it structurally similar to other members of the “cysteine knot growth factors” (CKGF) super family such as transforming growth factor beta (TGFβ), platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and bone morphogenic proteins [1]. This finding is consistent with observations linking high serum hCG levels with tumor neovascularization [9], as well as studies showing that addition of hCG may reverse the proapoptotic effects of TGFβ [10]. hCG may therefore stimulate growth of these tumors through agonistic and antagonistic interactions with receptors of other CKGFs.

Currently, the role of beta-hCG in osteosarcoma management is not well established. However, several prior studies demonstrated that β-hCG expressing tumors respond poorly to chemotherapy, and changes in serum levels correlate with relapse and response to treatment [3, 5, 6]. In Boss et al.’s patient, it was found that initial drops followed by increases in β-hCG levels corresponded with radiologic response to E7080, an investigational tyrosine kinase inhibitor that targets VEGFR-2 and VEGFR-3 with secondary activity against PDGFR-β, FGFR-1, and C-KIT. Taking these observations together, they hypothesized that β-hCG could mediate resistance to VEGF inhibition [3], consistent with prior reports of β-hCG interactions with CKGF superfamily receptors.

**Conflict of Interests**

The authors declare that there is no conflict of interests.

**References**

[1] R. K. Iles, P. J. Delves, and S. A. Butler, “Does hCG or hCGβ play a role in cancer cell biology?” *Molecular and Cellular Endocrinology*, vol. 329, no. 1-2, pp. 62–70, 2010.

[2] J. K. Kalra, R. Mir, L. B. Kahn, Z. Wessely, and A. B. Shah, “Osteogenic sarcoma producing human chorionic
gonadotrophin. Case report with immunohistochemical studies," *Cancer*, vol. 53, no. 10, pp. 2125–2128, 1984.

[3] B. E. Tuy, A. A. Obafemi, K. S. Beebe, and F. R. Patterson, "Case report: elevated serum beta human chorionic gonadotropin in a woman with osteosarcoma," *Clinical Orthopaedics and Related Research*, vol. 466, no. 4, pp. 997–1001, 2008.

[4] D. S. Boss, H. Glen, J. H. Beijnen et al., "Serum β-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report," *Tumori*, vol. 97, no. 1, pp. 109–114, 2011.

[5] K. Z. Masrouha, R. Khatab, A. Tawil et al., "A preliminary investigation of beta-hCG expression in patients with osteosarcoma," *Journal of Bone and Joint Surgery—Series B*, vol. 94, no. 3, pp. 419–424, 2012.

[6] B. Leidinger, S. Bielack, G. Koehler, V. Vieth, W. Winkelmann, and G. Gosheger, "High level of beta-hCG simulating pregnancy in recurrent osteosarcoma: case report and review of literature," *Journal of Cancer Research and Clinical Oncology*, vol. 130, no. 6, pp. 357–361, 2004.

[7] B. R. Oshrine, L. M. Sullivan, and N. J. Balamuth, "Ectopic production of β-hCG by osteosarcoma: a case report and review of the literature," *Journal of Pediatric Hematology/Oncology*, vol. 36, no. 3, pp. e202–e206, 2014.

[8] N. G. Ordonez, A. G. Ayala, A. K. Raymond, C. Plager, R. S. Benjamin, and N. A. Samaan, "Ectopic production of the β-subunit of human chorionic gonadotropin in osteosarcoma," *Archives of Pathology & Laboratory Medicine*, vol. 113, no. 4, pp. 416–419, 1989.

[9] O. Arrieta, R. M. Michel Ortega, J. Angeles-Sanchez et al., "Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors," *Journal of Experimental and Clinical Cancer Research*, vol. 28, no. 1, article 120, 2009.

[10] S. A. Butler, M. S. Ilkram, S. Mathieu, and R. K. Iles, “The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation," *British Journal of Cancer*, vol. 82, no. 9, pp. 1553–1556, 2000.